Esbriet

#ATS2018 – Esbriet Lowers Risk of Seasonal IPF Flares Leading to Hospitalizations, Phase 3 Data Show

Seasonal flares of disease activity that can lead to idiopathic pulmonary fibrosis (IPF) patients being hospitalized, especially in the winter months, appear to be effectively countered by treatment with Esbriet (pirfenidone) compared to placebo, a new retrospective analysis of data from Phase 3 clinical trials shows. Results were presented by Brett Ley,…